UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

4 Apr 2024

FDA Accepts Supplemental Biologics License Applications for BIMZELX[®] (bimekizumab-bkzx) for Moderate to Severe Hidradenitis Suppurativa and Additional 2mL Device Presentations

Read More
29 Mar 2024

Share Repurchase Program 2024 to cover UCB's Long Term Incentive Plans for employees

Read More
22 Mar 2024

UCB receives positive CHMP opinion for BIMZELX[®]▼(bimekizumab) for the treatment of adults with moderate to severe hidradenitis suppurativa

Read More
15 Mar 2024

UCB announces changes on Board of Directors

Read More
13 Mar 2024

UCB successfully completes institutional Eurobond issue

Read More
9 Mar 2024

First presentation of four-year BIMZELX[®](bimekizumab-bkzx) data showed long-term maintenance of complete skin clearance in moderate to severe plaque psoriasis

Read More

Stay up-to-date on the latest news and information from UCB